CDXC

Analyst Note: ChromaDex Corporation (CDXC)

Date: 2026-06-13 Current Price: $7.87

1. Structural Readiness

Aggressive/Pre-Breakout Entry: Not recommended as a standalone signal; the setup is currently in the "forming" phase, which carries a partial readiness signal but lacks the confirmation of a breakout. Breakout Level: Not yet defined in the provided data; this will be established once the resistance level is clearly identified and tested. Current Price: $7.87. Extension: Not applicable (price is not yet extended from a breakout). ATR Context: Current ATR is 6.1% (Very High). This indicates elevated volatility, which is a key input for position sizing but does not alter the structural state of the coil.

2. Thesis Layer

As of 2026-06-13, there is no named secular thesis driving this name. This is a TACTICAL, setup-led opportunity. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals (revenue growth, new product traction, and margin management). No macro or thematic thesis should be invented to support the position.

3. Business Overview

ChromaDex Corporation operates in the Consumer Products, Ingredients, and Analytical Reference Standards sectors. The company's core business model revolves around its proprietary ingredient, Niagen (nicotinamide riboside, an NAD+ precursor).

• Consumer Products: The company sells finished dietary supplements directly to consumers via its e-commerce site (TRUNIAGEN.com), Amazon, and other marketplaces. The flagship product is TRU NIAGEN.
• *Evidence:* Q1 2026 revenue for TRU NIAGEN grew 4% year-over-year to $22.4 million, driven by a 14% increase in e-commerce revenue to $19.2 million (E5).
• *Recent Developments:* The company pilot-launched Niagen Nanocloud (a topical skin care product) in March 2026, reporting "extremely strong" early demand and being "nearly sold out" ahead of a wide launch in October (E3). Additionally, the Niagen at-home injection kit launched over the weekend prior to the earnings call, with management describing the first 4-5 days of sales as "outstanding" (E4).
• Ingredients: This segment supplies Niagen to other manufacturers for use in their consumer products (food-grade and pharma-grade).
• *Evidence:* Niagen ingredient revenue was $8.2 million in Q1 2026, up 2% year-over-year. This includes $7.3 million in food-grade sales and $850,000 in pharma-grade sales (E6).
• Analytical Reference Standards: The company provides quality control services for raw materials and finished goods in dietary supplements, cosmetics, food, and life sciences (E13, E14).

Management Expectations:

• Top Line: Management reaffirmed guidance for 10% to 15% year-over-year growth for the full year (E1).
• Expenses: Management revised its outlook, expecting selling and marketing expenses to increase in absolute dollars and as a percentage of net sales, moving away from the previous expectation of stability (E2).
• Market Awareness: Management noted significant media attention, including features in the *L.A. Times*, *Wall Street Journal*, *Vogue*, and *GQ*, which they attribute to growing awareness of NAD+ benefits (E7).

4. Archetype and Conviction

Archetype: Quality Compounder.

• Rationale: The company demonstrates consistent revenue growth (10-15% guidance), a strong brand presence in the NAD+ space, and successful expansion into new product categories (topical, injectable). The business model is supported by a proprietary ingredient with multiple revenue streams (direct-to-consumer and B2B ingredients).
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.205 for FY1 and $0.235 for FY2 (E16).
• Conviction Stack:
• *Thesis Strength:* Low (Tactical, no macro thesis).
• *Evidence Quality:* High (Strong earnings data, clear product traction, specific revenue figures).
• *Structural Quality:* Moderate (Forming coil, high volatility).
• *Setup Readiness:* Partial (Forming, awaiting breakout).
• *Rerating Potential:* Moderate (Dependent on successful execution of new product launches and margin management amidst increased marketing spend).

ATR Analysis: The current ATR of 6.1% falls into the Very High bucket (6-8%). Historically, this level of volatility suggests elevated risk and requires careful position sizing. It is above the historical "sweet spot" (4-6%) and approaches the "extreme" threshold (>8%), which is associated with higher severe-loser rates. This volatility must be factored into the risk/reward assessment.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Failure of the new product launches (Niagen Nanocloud, injection kit) to meet management's "strong" demand expectations.
• Significant deterioration in margins beyond the stated increase in marketing spend, leading to a failure to meet the 10-15% growth guidance.

What Would Strengthen the Case:

• Continued strong sales data for the new product lines (Nanocloud, injection kit) in subsequent quarters.
• Successful management of the increased marketing spend to drive the projected 10-15% growth.

Gaps in Evidence:

• Detailed Margin Analysis: While management expects increased marketing spend, the specific impact on net margins is not detailed beyond the qualitative statement.
• Competitive Landscape: No specific data on competitive pressures or market share changes is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue growth of 5% YoY with TRU NIAGEN up 4% to $22.4M; Management reaffirmed 10-15% full-year growth guidance; New product launches (Nanocloud, injection kit) showing "extremely strong" early demand. Key risks: Very high ATR (6.1%) indicates elevated volatility and risk of sharp drawdowns; Increased marketing spend as a % of sales may pressure margins; Forming coil structure requires breakout confirmation before full conviction; No named secular thesis to provide macro tailwinds. Sizing hint: Reduce position size relative to historical norms due to very high ATR and forming (unconfirmed) setup state. Expected path: Price consolidates near current levels while new product launches gain traction; a breakout above resistance would confirm the setup and potentially drive further upside if growth targets are met. Expected horizon: 3-6 months for the setup to resolve (breakout or invalidation).